TheBrief.Health

The expiration of enhanced ACA subsidies is driving coverage losses, higher premiums, and underinsurance, increasing uncompensated care while straining patients, providers, and healthcare systems nationwide.

Emerging evidence suggests GLP-1 receptor agonists may reduce alcohol cravings and heavy drinking, offering a promising new treatment approach for alcohol use disorder, especially with obesity.

Endovascular pulmonary artery banding offers a less invasive alternative for selected infants with congenital heart disease, stabilizing pulmonary blood flow while delaying higher-risk open-heart surgery.

A large meta-analysis found people experiencing homelessness receive fewer time-critical stroke treatments, highlighting urgent needs for equitable triage, standardized care pathways, and stronger post-discharge support.

FDA clearance of a 4K fluorescence-guided exoscope enhances open surgery by improving visualization, teamwork, and real-time tissue perfusion assessment to support safer surgical decisions.

Updated pediatric heart guidelines promote earlier screening for sudden cardiac death risk, helping clinicians identify warning signs, order timely testing, and prevent life-threatening cardiac events.

New research suggests ARBs may better preserve long-term cognitive function than ACE inhibitors in some hypertensive adults, supporting more brain-conscious treatment decisions without changing current therapy universally.

Johnson & Johnson’s new FDA-approved EDOF intraocular lens expands cataract surgery options by improving vision across distances, reducing reading-glass dependence, and minimizing common visual disturbances.

New evidence supports sequential pembrolizumab after radiotherapy for high-risk Merkel cell carcinoma, reducing disease recurrence, preventing distant metastases, and reshaping multidisciplinary postoperative treatment strategies.

Heart–brain clinics unite neurologists and cardiologists to identify stroke causes faster, personalize prevention strategies, reduce recurrent strokes, streamline testing, and improve long-term patient outcomes.

A practical tricuspid regurgitation risk score combines symptoms, imaging, labs, and comorbidities to predict prognosis, guide timely referrals, personalize treatment, and improve patient outcomes.

Arizona’s first heart-in-a-box transplant showcases warm perfusion technology, extending donor heart preservation, expanding transplant opportunities, improving organ assessment, and offering hope for patients nationwide awaiting.

New baby food rules require public testing for lead, arsenic, cadmium, and mercury, improving transparency, guiding safer choices, and encouraging manufacturers to reduce contamination.

Large real-world study found no meaningful dementia risk differences between apixaban, edoxaban, and rivaroxaban, supporting DOAC selection based on safety, adherence, renal function, and patient needs.

Large real-world study found apixaban, edoxaban, and rivaroxaban offer similar dementia protection in atrial fibrillation, allowing clinicians to prioritize safety, adherence, and patient-specific factors.

A structured low-GI Mediterranean diet, daily brisk walking, and vitamin D supplementation significantly reduced recurrence risk in HR-positive breast cancer survivors while improving metabolic health.

Adagio Medical’s FDA submission for its ultra-low temperature ventricular ablation system could expand treatment options for drug-refractory ventricular tachycardia, offering deeper lesion creation, fewer ICD shocks, reduced antiarrhythmic dependence, and improved procedural outcomes.

FDA’s Red No. 3 ban will phase the dye out of foods and medicines by 2027, prompting reformulations while reassuring consumers about minimal health risk.

Reflow Medical’s retrievable sirolimus-eluting coronary scaffold aims to treat in-stent restenosis without permanent metal, potentially improving vessel healing while preserving future treatment options.

Neurovalens’ Modius platform brings noninvasive neuromodulation into clinical practice, offering home-based FDA-authorized therapies for insomnia, anxiety, PTSD, and weight management, while facing evidence, reimbursement, and adoption challenges.

Menin inhibitors revumenib and ziftomenib target key leukemia-driving mutations, improving remission rates, enabling transplant opportunities, and advancing precision treatment for relapsed acute leukemias.

AI-powered ECG and ultrasound tools can identify silent left ventricular systolic dysfunction earlier, enabling timely evaluation, targeted treatment, and improved heart failure prevention and outcomes.

A new generation of oral HER2-targeted therapies is transforming advanced NSCLC care, delivering durable responses, brain metastasis control, and personalized treatment beyond traditional chemotherapy.

A newly approved c-Met–targeted antibody-drug conjugate offers a precision treatment option for previously treated advanced non-squamous NSCLC, expanding personalized therapy beyond genomic mutations alone.

FDA approval of Tzield marks a breakthrough in Type 1 diabetes care, preserving remaining insulin-producing cells and shifting treatment from replacement to disease modification.

N-acetylcysteine (NAC) shows promise as a neuroprotective adjunct in acute ischemic stroke, potentially preserving brain tissue, enhancing reperfusion outcomes, and improving recovery during treatment delays.

A novel 44-metabolite signature improves prediction of future type 2 diabetes risk, enabling earlier identification of high-risk individuals and supporting personalized prevention strategies.

Digital health and telemedicine are transforming healthcare delivery through virtual care, remote monitoring, and enhanced patient engagement, improving access, efficiency, outcomes, and care coordination.

FDA scrutiny of PFAS “forever chemicals” in cosmetics may drive stricter regulations, reformulated products, greater labeling transparency, and increased consumer demand for safer beauty options.

The FDA’s approval of teplizumab for newly diagnosed pediatric Type 1 diabetes marks a shift from insulin replacement toward preserving remaining beta-cell function through immunotherapy.

The investigational Vertex Pulmonary Embolectomy System demonstrated promising results in intermediate-risk pulmonary embolism, improving right-heart function and pulmonary pressures while supporting safer, catheter-based clot removal.

Rapid measles response is critical for infants, who remain highly vulnerable before routine vaccination. Early exposure management, timely immunization, isolation protocols, and coordinated public health action help prevent severe complications, limit transmission, and protect young children during outbreaks.

Advanced carotid plaque imaging evaluates plaque biology, helping clinicians identify stroke risk more accurately, personalize treatment decisions, and improve prevention beyond stenosis measurement alone.

A novel smart device for heart failure decongestion uses pressure-guided fluid redistribution to reduce congestion, potentially improving symptoms, lowering hospitalizations, and enabling remote monitoring.

Metabolomic profiling is emerging as a promising tool for predicting asthma exacerbations, enabling earlier risk identification, personalized treatment strategies, and potentially reducing hospitalizations through proactive disease management.

ECAP-guided spinal cord stimulation enables real-time, adaptive pain management, offering more consistent symptom relief and reducing reliance on opioids for chronic pain patients.

Emerging obesity treatments may deliver both weight-loss and cardiovascular benefits, offering new options to reduce heart disease risk while addressing the growing obesity epidemic.

Retinal imaging may offer a noninvasive way to detect early Alzheimer’s-related brain changes, supporting earlier screening, risk assessment, and referral before significant cognitive decline occurs.

A 24-year U.S. analysis shows gene-targeted therapies dramatically reduced childhood spinal muscular atrophy mortality, transforming a once-fatal disease into a manageable long-term condition.

ASCO 2026 data suggest first-line talazoparib plus enzalutamide significantly delays progression in HRR-mutated metastatic prostate cancer, highlighting the growing importance of early genomic testing and biomarker-driven treatment.

A landmark study found the APOE ε4 gene was not linked to vascular brain injury progression in American Indians, highlighting the importance of cardiometabolic risk management.

The RADIOS consortium studies immune-related side effects of cancer immunotherapy, helping researchers improve treatment safety, personalize care, and optimize outcomes for patients receiving checkpoint inhibitors.

Physically demanding occupations may increase autoimmune disease risk in men, particularly inflammatory joint conditions, highlighting the importance of workplace prevention, early screening, and risk assessment.

Post-bariatric surgery success depends on consistent long-term care. Multidisciplinary follow-up helps prevent complications, supports mental and metabolic health, and sustains weight-loss outcomes.

Daily movement patterns may predict long-term health outcomes in people with knee osteoarthritis. Regular moderate activity supports symptom management, lowers mortality risk, and informs personalized care.

This review examines 7-year CROWN trial data showing lorlatinib’s unprecedented durability in ALK-positive NSCLC, highlighting survival gains, CNS protection, resistance suppression, and toxicity management.

Advanced heart failure is when symptoms worsen despite optimal medical treatment, making daily activities difficult. In this stage, early referral to a specialty team is critical for patients who may benefit from advanced therapies like LVAD, transplant, or palliative inotropes to prolong survival.

Reviewing Neuralink’s first clinical implant, this briefing examines brain-computer interfaces, patient impact, healthcare readiness, reimbursement, ethics, rehabilitation, and future integration into care delivery models nationwide.

One-year data suggest Abbott’s Navitor TAVI system delivers strong valve performance, low complications, and improved future coronary access planning for severe aortic stenosis patients.

Safe infant sleep requires consistent education, practical support, and accessible sleep spaces, helping families follow evidence-based practices that reduce SIDS and sleep-related deaths.